These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 33650148)

  • 1. cLRT-Mod: An efficient methodology for pharmacometric model-based analysis of longitudinal phase II dose finding studies under model uncertainty.
    Buatois S; Ueckert S; Frey N; Retout S; Mentré F
    Stat Med; 2021 May; 40(10):2435-2451. PubMed ID: 33650148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of dose-response for count data using a generalized MCP-Mod approach in an adaptive dose-ranging trial.
    Mercier F; Bornkamp B; Ohlssen D; Wallstroem E
    Pharm Stat; 2015; 14(4):359-67. PubMed ID: 26083135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confirmatory efficacy testing for individual dose-placebo comparisons using serial gatekeeping procedure in dose-finding trials with multiple comparison procedures-modeling.
    Yamaguchi Y; Sugitani T; Yoshida S; Maruo K
    Pharm Stat; 2022 Nov; 21(6):1309-1323. PubMed ID: 35708144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statistical considerations in model-based dose finding for binary responses under model uncertainty.
    Yan Z; Yang M
    Stat Med; 2024 May; 43(12):2472-2485. PubMed ID: 38605556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calculation of Phase 2 dose-finding study sample size for reliable Phase 3 dose selection.
    Liu F; Zhao Q; Rodgers AJ; Mehrotra DV
    Pharm Stat; 2023; 22(6):1076-1088. PubMed ID: 37550963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical considerations on implementing the MCP-Mod method for binary endpoints in clinical trials.
    Chen J; Liu T
    Contemp Clin Trials Commun; 2020 Sep; 19():100641. PubMed ID: 32875139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power and sample size for dose-finding studies with survival endpoints under model uncertainty.
    Deng Q; Bai X; Liu D; Roy D; Ying Z; Lin DY
    Biometrics; 2019 Mar; 75(1):308-314. PubMed ID: 30203467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection.
    Aoki Y; Röshammar D; Hamrén B; Hooker AC
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):581-597. PubMed ID: 29103208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-based dose finding under model uncertainty using general parametric models.
    Pinheiro J; Bornkamp B; Glimm E; Bretz F
    Stat Med; 2014 May; 33(10):1646-61. PubMed ID: 24302486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.
    Buatois S; Ueckert S; Frey N; Retout S; Mentré F
    AAPS J; 2018 Mar; 20(3):56. PubMed ID: 29600418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMA-Mod: A Bayesian model averaging strategy for determining dose-response relationships in the presence of model uncertainty.
    Gould AL
    Biom J; 2019 Sep; 61(5):1141-1159. PubMed ID: 30565273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-ranging design and analysis methods to identify the minimum effective dose (MED).
    Zhou Y; Chen S; Sullivan D; Li Y; Zhang Y; Xie W; Zhang H; Tang Y; Wang L; Hartford A; Yang B
    Contemp Clin Trials; 2017 Dec; 63():59-66. PubMed ID: 28818433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination MCP-Mod for two-drug combination dose-ranging studies.
    Zhou Y; Sloan A; Menon S; Wang L
    J Biopharm Stat; 2024 Feb; ():1-14. PubMed ID: 38335371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case study of model-based Bayesian dose response estimation.
    Tan H; Gruben D; French J; Thomas N
    Stat Med; 2011 Sep; 30(21):2622-33. PubMed ID: 21713966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding studies, MCP-Mod, model selection, and model averaging: Two applications in the real world.
    Verrier D; Sivapregassam S; Solente AC
    Clin Trials; 2014 Aug; 11(4):476-484. PubMed ID: 24872360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose response signal detection under model uncertainty.
    Dette H; Titoff S; Volgushev S; Bretz F
    Biometrics; 2015 Dec; 71(4):996-1008. PubMed ID: 26228796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multiple comparison procedure for dose-finding trials with subpopulations.
    Thomas M; Bornkamp B; Posch M; König F
    Biom J; 2020 Jan; 62(1):53-68. PubMed ID: 31544265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved inference for MCP-Mod approach using time-to-event endpoints with small sample sizes.
    Diniz MA; Gallardo DI; Magalhães TM
    Pharm Stat; 2023; 22(5):760-772. PubMed ID: 37119000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An empirical comparison of Bayesian modelling strategies for missing binary outcome data in network meta-analysis.
    Spineli LM
    BMC Med Res Methodol; 2019 Apr; 19(1):86. PubMed ID: 31018836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive dose-finding based on safety and feasibility in early-phase clinical trials of adoptive cell immunotherapy.
    Wages NA; Fadul CE
    Clin Trials; 2020 Apr; 17(2):157-165. PubMed ID: 31856602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.